Insight

Erman Akkus: Pancreatic cancer clinical trials in AACR24

Photo of Erman Akkus taken from mn.uio.no

Apr 12, 2024, 14:08

Erman Akkus: Pancreatic cancer clinical trials in AACR24

Erman Akkus, Medical Oncology Fellow at Ankara University, shared on X:

“Pancreatic cancer clinical trials in AACR24:

CT022 – Mutant KRAS peptide-based vaccine in patients at high risk of developing pancreatic cancer. mKRAS-specific T cell response induced.
CT134 – Neoadjuvant/adjuvant GM-CSF-secreting allogeneic pancreatic tumor cell vaccine (GVAX) combined with cyclophosphamide, pembrolizumab, and macrophage-targeting CSF1R inhibitor IMC-CS4. Safe and significantly increased activated CD8+ T cells.
CT025 – Personalized RNA neoantigen vaccines (autogenous cerumen). Induces polyfunctional CD8+ T effector cells of significant longevity, substantial magnitude, and durable function.
CT031 -Neoadjuvant modified FOLFIRINOX plus nivolumab in borderline resectable pancreas cancer. Favorable rates of R0 resection, PFS, and OS.
CT016 -Entinostat plus nivolumab. Immunomodulation of myeloid cell populations
CT080 / 7 -Devimistat plus chemoradiation in inoperable pancreatic cancer. Safe and well tolerated, trial in progress.
CT106 / 14 – Paclitaxel-eluting PTM-101 film in borderline resectable or locally advanced pancreatic cancer. Surgically feasible, safe, resulted in no systemic paclitaxel exposure, and caused a tumor size reduction.
CT107 / 15 – Lymph node targeted mKRAS-specific amphiphile vaccine. Durable immunogenicity.
Siltuximab plus spartalizumab in advanced pancreatic cancer. Safe but did not elicit responses.
CT214 / 14 – Paricalcitol plus chemotherapy in metastatic pancreatic cancer. Limited clinical benefit.
Minnelid in chemotherapy-refractory metastatic pancreatic cancer. Safe but did not elicit responses.
Narmafotinib plus gemcitabine and nab-paclitaxel as first-line therapy in patients with advanced pancreatic cancer (ACCENT trial). Safe and PR in 47% of patients.”

Source: Erman Akkus/X

AACR24 ACCENT trial. Adjuvant Amphiphile vaccine Ankara University Autogenous cerumen cancer chemoradiation chemotherapy clinical trials Devimistat Entinostat Erman Akkus FOLFIRINOX Gemcitabine GM-CSF-secreting allogeneic pancreatic tumor cell vaccine GVAX IMC-CS4 Lymph node targeted Macrophage-targeting CSF1R inhibitor Medical Oncology Fellow Minnelid mKRAS-specific T cell response Mutant KRAS peptide-based vaccine nab-paclitaxel Narmafotinib Neoadjuvant nivolumab OncoDaily Oncology Pancreatic Cancer Paricalcitol pembrolizumab Personalized RNA neoantigen vaccines PTM-101 film Siltuximab Spartalizumab

Esophageal Cancer: Symptoms, Causes, Stages, Diagnosis & Treatment

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Special Coverage